Recursion Pharmaceuticals, Inc. (RXRX) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Recursion's CFO Ben Taylor, who joined via the Exscientia merger roughly 18 months ago after serving as Exscientia's CFO & CSO, gave background on his role and the company's transition. He highlighted prior operational experience running an oncology biotech and framed Recursion's focus on AI-driven drug discovery as a response to sparse data in traditional development.

Analysis

Recursion sits at the intersection of high-fixed-cost AI infrastructure and low-marginal-cost drug development; the non-obvious lever is margin reallocation rather than immediate top-line growth. If the platform meaningfully reduces the per-program discovery cost by even 20–40% it will compress demand for traditional outsourced R&D (CROs) and redirect economics to whoever owns the models and data, creating a multi-year shift in pharma spend patterns.

Execution risk is multi-modal: near-term volatility will be driven by event cadence (data readouts, partner announcements) over the next 3–12 months, while model generalizability and regulatory acceptance drive value realization over 12–36 months. A single failed clinical read or a regulatory demand for provenance and prospective validation could reset expectations by 30–60% quickly; conversely, a credible partnership or pharma takeout term sheet would be a high-conviction positive catalyst.

Second-order winners include cloud/AI infrastructure providers and GPU-heavy supply chains that benefit from recurring model training needs; losers are mid-sized CROs that rely on discovery-to-indication services and could see margins pressured as platform-native workflows scale. Also watch M&A flow: platform owners become natural targets for large pharma aiming to internalize discovery economics, which compresses public comparables but raises takeover value ceilings.

From a market-structure angle, the stock will likely trade as a hybrid tech/biotech story, producing outsized implied-volatility moves around binary milestones — that creates attractive option-based, event-driven trade mechanics if calibrated to the right timelines and hedged for clinical/regulatory risk.

Key Decisions for Investors

• Initiate a core-long RXRX position (2–4% NAV) with a 12–24 month horizon; hedge tail risk by buying 12-month protective puts sized to cap portfolio drawdown at ~30–40%. R/R: asymmetric — 50–100% upside on positive platform validation/partnerships vs capped downside via puts.
• Buy LEAPS to express convexity: purchase RXRX Jan 2027 call options (small allocation 1–2% NAV) to capture multi-quarter de-risking; if IV rises after an announced partnership, consider converting to a covered-call or call spread to lock profits. R/R: 3x+ upside if platform drives licensing/M&A activity; full premium loss if tech/clinical readouts disappoint.
• Pair trade for structural exposure: long NVDA (0.5–1% NAV) vs short IQV (0.5% NAV) over 6–18 months to play infrastructure beneficiaries vs traditional CRO compression. R/R: NVDA captures secular AI spend; IQV short benefits if discovery spend shifts in-house — stop-loss at 20% for either leg to limit regime risk.
• Event-driven short-dated trade: sell covered/OTM calls on RXRX for 2–8 week windows following non-catalyst earnings to capture IV decay; avoid around scheduled clinical readouts or partnership announcements. R/R: collect premium with defined upside cap — risk is sharp gap-up on positive binary news, so keep sizing small (<=1% NAV).